These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724 [TBL] [Abstract][Full Text] [Related]
47. Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance. Jiang Z; Li Y; Zhou X; Wen J; Zheng P; Zhu W Bioorg Med Chem; 2024 Feb; 100():117627. PubMed ID: 38310752 [TBL] [Abstract][Full Text] [Related]
48. Mechanisms of isoform-specific residue influence on GTP-bound HRas, KRas, and NRas. Volmar AY; Guterres H; Zhou H; Reid D; Pavlopoulos S; Makowski L; Mattos C Biophys J; 2022 Oct; 121(19):3616-3629. PubMed ID: 35794829 [TBL] [Abstract][Full Text] [Related]
49. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128 [TBL] [Abstract][Full Text] [Related]
50. Molecular Basis for Allosteric Inhibition of GTP-Bound H-Ras Protein by a Small-Molecule Compound Carrying a Naphthalene Ring. Matsumoto S; Hiraga T; Hayashi Y; Yoshikawa Y; Tsuda C; Araki M; Neya M; Shima F; Kataoka T Biochemistry; 2018 Sep; 57(36):5350-5358. PubMed ID: 30141910 [TBL] [Abstract][Full Text] [Related]
51. From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Chen Y; Liu QP; Xie H; Ding J Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578 [TBL] [Abstract][Full Text] [Related]
52. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review). Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636 [TBL] [Abstract][Full Text] [Related]
53. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830 [TBL] [Abstract][Full Text] [Related]
54. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681 [TBL] [Abstract][Full Text] [Related]
55. Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity. Imaizumi T; Akaiwa M; Abe T; Nigawara T; Koike T; Satake Y; Watanabe K; Kaneko O; Amano Y; Mori K; Yamanaka Y; Nagashima T; Shimazaki M; Kuramoto K Bioorg Med Chem; 2022 Oct; 71():116949. PubMed ID: 35926326 [TBL] [Abstract][Full Text] [Related]
56. The Research Progress of Direct KRAS G12C Mutation Inhibitors. Yang A; Li M; Fang M Pathol Oncol Res; 2021; 27():631095. PubMed ID: 34257597 [No Abstract] [Full Text] [Related]
57. Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells. Kumazaki M; Shimomura I; Kiyono T; Ochiya T; Yamamoto Y Biochem Biophys Res Commun; 2020 Apr; 525(2):483-490. PubMed ID: 32111352 [TBL] [Abstract][Full Text] [Related]
58. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. Roskoski R Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320 [TBL] [Abstract][Full Text] [Related]
59. Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors. Poorebrahim M; Abazari MF; Moradi L; Shahbazi B; Mahmoudi R; Kalhor H; Askari H; Teimoori-Toolabi L PLoS Comput Biol; 2022 Apr; 18(4):e1009962. PubMed ID: 35472201 [TBL] [Abstract][Full Text] [Related]